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Intravenous injection of Klebsiella O3 lipopolysaccharide (LPS) into BALB/c mice induces an anaphylaxis-like shock within minutes. Using
5-hydroxytryptamine as a marker for platelets, we previously suggested that a rapid platelet accumulation in the liver and lung precedes the shock,
and that a complement-dependent platelet-degradation is involved in the shock. Here, we examined (i) the effect of platelet-depletion (using an
anti-platelet monoclonal antibody) on the shock and (ii) the contribution of macrophages to the platelet-accumulation in those organs. LPS-
induced platelet-accumulations in the liver and lung were confirmed by immunostaining. In platelet-depleted mice, the shock was largely
prevented. The number of F4/80-positive macrophages was much greater in liver than in lung, and the hepatic macrophages were largely lost in
mice given clodronate-encapsulated liposomes. In mice treated with such liposomes, both the LPS-induced accumulation of platelets in the liver
(but not in the lung) and the shock were largely prevented, and repopulation of hepatic macrophages restored these LPS-induced responses. These
results suggest that (i) platelets are indeed involved in the shock, (ii) Kupffer cells mediate the hepatic platelet accumulation, and (iii) preventing
this hepatic accumulation can largely prevent rapid shock being induced by LPS (at the dose used here).
© 2005 Elsevier B.V. All rights reserved.Keywords: Platelet; Lipopolysaccharide; Liver; Lung; Shock; Macrophage1. Introduction
Traditionally, platelets have been considered to play major
roles in hemostasis. However, recent studies suggest that
another fundamental physiological role of platelets lies in the
defense against invasion by foreign organisms, and thatAbbreviations: Clo-Lip, clodronate-encapsulated liposomes; HPA, hepatic
platelet accumulation; 5HT, 5-hydroxytryptamine; LPS, lipopolysaccharide;
PBS, phosphate-buffered saline; PPA, pulmonary platelet accumulation
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doi:10.1016/j.bbadis.2005.11.010platelets are involved in inflammatory reactions during
immune responses [1–4].
Lipopolysaccharide (LPS) is a constituent of the cell wall of
gram-negative bacteria with the potential to induce various non-
specific immune responses [5,6]. Using 5-hydroxytryptamine
(5HT) as a marker for platelets, we previously observed a
unique response by platelets to LPS [7–11]. Briefly, within a
few minutes of the intravenous injection into mice of a certain
type of LPS, platelets accumulate in the liver (at lower doses of
LPS) and in both the liver and lung (at higher doses). Thus, the
liver is more sensitive to LPS than the lung in terms of the
accumulation of platelets. In addition to its dependence of the
dose of LPS, this platelet response also depends on the structure
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pathway of the complement system. At their maximal levels, the
LPS-induced pulmonary platelet accumulation (PPA) and
hepatic platelet accumulation (HPA) reach about 80% and
30%, respectively, of the total numbers of circulating platelets.
When the response is weak or the LPS dose is low, the platelets
that have accumulated in these organs soon return to the
circulation. When the response is strong or the LPS dose is high,
degradation (or destruction) of platelets occurs in the lung [7,9]
and possibly in the liver [8]. However, the mechanism by which
platelets accumulate in these organs remains to be clarified.
It is known that platelets produce and/or store a variety of
inflammatory substances, such as thromboxane A2, 5HT,
adrenaline, histamine, and PAF [3,4], and these substances are
known to induce shock at pharmacological doses. Indeed,
within 5 to 10 min of an intravenous LPS injection,
anaphylaxis-like rapid shock occurs when there is a degradation
of platelets in the lung and/or liver [7–9]. An inhibitor of
complement C5 prevents both the degradation of platelets and
the development of the shock, although it does not reduce the
PPA and HPA themselves [8,11]. In addition, in mice deficient
in complement C5, platelets accumulate in the liver and lung in
response to LPS, but soon return to the circulation without
degradation, and there is no rapid shock [8,11]. These results
suggest that it is the degradation of platelets in the lung and/or
liver that is the cause of the anaphylaxis-like shock (i.e., the
PPA and HPA themselves are not the direct cause of the rapid
shock). However, it is not clear which organ, the lung or the
liver, makes the greater contribution to the induction of the
shock.
In addition to the rapid platelet responses described above,
LPS induces another type of HPA, which occurs some hours
after its injection [7,9,12]. We tentatively call this “slow HPA”
as opposed to the “rapid HPA” described above. The slow HPA
is induced even by the intraperitoneal injection of a very low
dose of LPS. Interestingly, the LPS-induced slow HPA has been
shown to be largely absent in mice depleted of their Kupffer
cells (hepatic phagocytic macrophages) [13] in experiment
making use of the finding that phagocytic macrophages can be
selectively depleted by an intravenous injection of liposomes
encapsulated with clodronate [14].
In the present study, as an approach to clarifying the
mechanism by which platelets accumulate rapidly in the liver
and lung, we examined the effects of depletion of phagocytic
macrophages on the Klebsiella O3 LPS-induced rapid HPA,
rapid PPA, and anaphylaxis-like shock in BALB/c mice.
2. Materials and methods
2.1. Animals and materials
Male BALB/c mice obtained from the animal facility of our university were
used in the experiments. Clodronate (dichloromethylene bisphosphonate) was
purchased from Sigma (St. Louis MO, USA). A rat monoclonal antibody to
mouse F4/80 antigen was purchased from Serotec (Kidlington, UK). The
hybridoma cells employed to produce a monoclonal rat anti-mouse platelet
antibody, Pm-1, were provided by Dr. T. Nagasawa (Division of Hematology,
University of Tsukuba, Japan) [15]. This antibody was produced in the
peritoneal cavity in BALB/c nude mice inoculated with the hybridoma cells, anda preparation (IgG fraction) of the antibody was obtained by precipitation with
ammonium sulfate and dialysis of the precipitant. Control mouse IgG was
prepared by precipitation with ammonium sulfate. LPS from the Klebsiella O3
strain LEN-1 (S type) was prepared using the phenol–water method [16],
dissolved in sterile saline, and injected intravenously via the tail (0.1 ml per 10 g
body weight). The injection of LPS was carried out at a room temperature of 26–
28 °C. All experiments complied with the Guidelines for Care and Use of
Laboratory Animals in Tohoku University. Experimental protocols and doses of
these reagents are described in the text or in the legend to the figure or table
relating to each experiment.
2.2. Depletion and detection of macrophages
Clodronate-encapsulated liposomes (Clo-Lip) have been shown to deplete
phagocytic macrophages, but not dendritic cells and neutrophils [14]. A
suspension of Clo-Lip was prepared by a method similar to that used by Van
Rooijen and his coworkers [14], as described previously [17]. Briefly, 75 mg of
phosphatidylcholine and 11 mg of cholesterol were dissolved in chloroform (20
ml) in a round-bottomed flask (1000ml). The thin film that formed on thewalls of
the flask after rotary evaporation at 37 °C was dispersed by gentle shaking for 10
min in 10 ml of clodronate solution (200 mg/ml) in 10 mM sodium phosphate
buffer (PBS, pH 7.4). This suspension was kept for 2 h at room temperature, then
sonicated for 3 min (50 Hz) and kept for another 2 h. The resulting liposomes
floating on the aqueous phase were collected by Pasteur pipette, then suspended
in 10 ml of PBS and centrifuged at 5000×g for 30 min. The precipitated
liposomes were finally suspended in 4 ml of PBS; this preparation is hereafter
referred to as the “original clodronate-liposomes”. This original suspension was
diluted (as described in the text) with PBS and the resulting suspension was
injected intravenously via the tail into mice at 0.2 ml/mouse.
2.3. Platelet count
Two or three drops of blood from each decapitated mouse were directly
collected into a pre-weighed test tube containing 1.0ml of 4mMEDTA in 0.01M
PBS (pH 7.0). The tube plus blood was weighed, and the volume of blood was
estimated from the weight of the blood. The number of platelets was then
ascertained using a cell counter, Sysmex SF-3000 (Toa Medical Electronics Co.
Ltd., Kobe, Japan).
2.4. Estimation of HPA and PPA
HPA and PPAwere estimated by measuring 5HTas described previously [7–
11]. Briefly, after collection of the blood for measuring the platelet count (see
above), the next two or three drops of blood from the same mouse were collected
into another pre-weighed tube containing 3 ml of 0.4 M HClO4 containing 0.2%
N-acetylcysteine–HCl and 4 mM EDTA-2Na. After reweighing, the platelets
were destroyed by sonication, and each tube was cooled in an ice bath. The lungs
and liver were rapidly removed after collection of the blood, and the 5HT in
these tissues was also extracted with 0.4 M HClO4 containing N-acetylcysteine–
HCl and EDTA-2Na. The 5HT extracted from the blood and tissues was
separated by column chromatography, and measured fluorometrically as
previously described [12].
2.5. Immunostaining of macrophages
Macrophages in livers and lungs were detected by immunohistochemical
staining of F4/80 antigen using its monoclonal antibody (see above). F4/80 is
expressed specifically on the surface of these cells [18,19]. Specimens of lungs
and livers were fixed in 4% paraformaldehyde phosphate buffer and embedded in
paraffin. Serial sections from tissue blocks were deparaffinized and immersed in
ethanol containing 0.3% hydrogen peroxide. After treatment with 3% skim milk
for 30 min, the sections were incubated with rat anti-mouse F4/80 antigen
monoclonal antibody (20 μg/ml) at 4 °C overnight. The sections were allowed to
react with peroxidase-conjugated ant-rat IgG polyclonal antibody (Histofine
Simple Stain MAX-PO) (Nichirei, Tokyo Japan) for 30 min, and the reaction
products were visualized by immersing the sections for 2 to 3 min in 0.03%
diaminobenzidine solution containing 2 mM hydrogen peroxide. Nuclei were
lightly stained with methyl green.
Fig. 1. Effects of Pm-1 on platelet count and on 5HT in the blood and tissues.
Pm-1 (10 mg/kg) was injected subcutaneously and the blood and tissues of the
mouse were removed at the time-points indicated. Each value is the mean±S.D.
for 4 mice. *Pb0.01 vs. time 0.
Table 1
Effect of platelet depletion by Pm-1 on LPS-induced anaphylaxis-like shock
Treatment Shock score
cIgG→LPS 3, 3, 3, 4, 4
Pm-1→LPS 0, 0, 0, 0, 1
Two groups of mice (n=5 each) were subcutaneously injected with control IgG
(cIgG) or Pm-1 (10 mg/kg each). Then, 12 h later, LPS was injected
intravenously (1 mg/kg). The shock score indicates the maximum points
allocated for the signs of shock observed within 30 min of the LPS injection.
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Platelets accumulated in livers and lungs were detected using the anti-
platelet antibody Pm-1 (see above). Sections of lungs and livers were
embedded in Tissue-Tek OCT Compound (Sakura Finetechnical, Tokyo,
Japan), then quick-frozen in a mixture of acetone and dry ice. Serial cryostat
sections cut at 5 μm thick from each frozen block were fixed in 4%
paraformaldehyde phosphate buffer for 10 min, then washed in cold
phosphate-buffered saline. After treatment with normal rabbit and goat sera
for 20 min, the sections were incubated with Pm-1 (6.3 μg/ml) at 4 °C
overnight. The sections were allowed to react with peroxidase-conjugated anti-
rat IgG polyclonal antibody (see above) for 30 min, and the reaction products
were visualized by immersing the sections for 2 to 3 min in 0.03%
diaminobenzidine solution containing 2 mM hydrogen peroxide. Nuclei were
lightly stained with hematoxylin.Fig. 2. Effects of Clo-Lip on platelets and macrophages. (A) Saline or Clo-Lip (diluted
the mouse was taken and subjected to platelet counting. Each value is the mean
immunostaining with F4/80 antibody, and representative results are shown. There are
almost absent from the liver of Clo-Lip-treated mice. In the lung, however, almost no F
Noted that the magnification for microscopy is the same for liver and lung.2.7. Scoring of shock
The maximal score given to the severity of the rapid anaphylactoid shock in
each mouse within 30 min of LPS injection was recorded as described
previously [11]. The scoring of the shock was as follows: 0 (no symptoms of
shock), 1 (staggering), 2 (crawling and prostration), 3 (prostration and weak
convulsions), 4 (prostration and strong convulsions), and 5 (death).
2.8. Statistical analysis
Experimental values are given as the mean±standard deviation (SD). The
statistical significance of differences was analyzed using a Bonferroni post hoc
test, P values less than 0.05 being considered to indicate significance.
3. Results
3.1. Effects of platelet depletion on the LPS-induced rapid
shock
A single subcutaneous injection of Pm-1 at 10 mg/kg
markedly reduced both the platelet count and 5HTconcentration
in blood after 12 h (Fig. 1). In addition, the 5HT in the liver and
lung had disappeared almost completely at 24 h after the Pm-1
injection, while the magnitude of the depletion in the spleen was
smaller. These results indicate that 5HT in the blood, liver, and
lung is contained mostly in platelets. As the half-life of free 5HT
in the blood of mice is less than 10 s [20], the measured amount
of 5HT in the liver and lung may represent almost entirely the
amount of 5HT contained in the platelets located within these
organs. Despite this profound thrombocytopenia, there was no8-fold) (0.2 ml/mouse) was injected intravenously, and 2 days later the blood of
±S.D. for 4 mice. (B) The livers and lungs of the mice were subjected to
many F4/80-positive cells (brown) in the liver of saline-treated mice, but they are
4/80-positive cells were detected in either saline-treated or Clo-Lip-treated mice.
Fig. 3. Effects of Clo-Lip on LPS-induced rapid HPA and PPA. Saline (S) or 8-
fold-diluted Clo-Lip was injected intravenously (0.2 ml/mouse). Two days later,
LPS was injected intravenously (0.5 mg/kg). The mice were killed 5 min after
the LPS injection. Each value is the mean±S.D. for 4 mice. *Pb0.01 vs. S+S,
#Pb0.01 vs. S+LPS, $Pb0.05 vs. Clo-Lip+S.
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progressively from 2 days after the injection of Pm-1 (data not
shown). The severity of the shock induced by LPS (1 mg/kg)
was greatly reduced in mice given Pm-1 at 12 h before the
injection of LPS (Table 1). These results indicate that 5HT can
be a marker of platelet translocation from the blood to the liver
and lung, and that platelets are indeed involved in the LPS-
induced anaphylaxis-like shock.
3.2. Effects of Clo-Lip on platelets and hepatic macrophages
Our previous data indicated that at higher concentrations,
Clo-Lip reduces the number of platelets as well as that of
phagocytic macrophages [21]. Thus, in the present study we
injected an 8-fold diluted suspension of the original Clo-Lip.
This injection did not reduce the number of platelets found in
the blood 2 days later (Fig. 2A), but it largely eliminated F4/80-
positive cells (macrophages) from the liver (Figs. 2B and 5).
However, in the lung, F4/80-positive cells were scarce even in
control mice (Fig. 2B) and the number detected was insufficient
to allow us to evaluate the effect of Clo-Lip (it should be noted
that in Fig. 2, the magnification for microscopy is the same for
liver and lung). In the present study, we used saline-injectedFig. 4. Histochemical demonstration of platelets in the liver (A) and lung (B) at 5 min
subjected to immunostaining with Pm-1 antibody, and representative results are sho
much greater in LPS-injected mice. In the liver, the staining is localized around sinu
treated mice. Note that there is significant Pm-1 staining in the lung even of saline-trea
in the lung than in the liver (compare the 5HT levels in the lung and liver at time 0 in
much dilated.mice as a control, because liposomes that contain PBS alone
modulate the responses of macrophages [22].
3.3. Effects of Clo-Lip on the rapid HPA, PPA and
anaphylaxis-like shock
As shown in Fig. 3, an intravenous injection of LPS (0.5 mg/
kg) induced a marked increase in 5HT in the liver and lung at 5
min. Immunostaining of platelets with Pm-1 antibody demon-
strated that this 5HT elevation in the liver and lung reflects HPA
and PPA (Fig. 4). The rapid increase in 5HT in the liver was
largely absent in mice given Clo-Lip at 2 days before the LPS
injection (Fig. 3). However, no significant effect of Clo-Lip was
seen in the lung (Fig. 3). It should also be noted that the increase
in 5HT in the lung in response to LPS was about 10-fold greater
than that in the liver in terms of nmol/g, although F4/80-positive
cells in the lung were so few that we could hardly detect them
(Fig. 2B).
Another notable point is that although much less 5HT
accumulated in the liver than in the lung in terms of nmol/g, the
total amount of 5HT accumulated in the liver was not smaller
than that in the lung. From the 5HT values shown in Fig. 3 and
the weights of the liver (about 1.40 g) and lung (about 0.10 g),
the total amounts of 5HT in the liver and lung were calculated as
4.5 nmol and 3.8 nmol, respectively.
LPS at 1 mg/kg induced significant shock signs including
staggering, crawling, prostration, and convulsions (Table 2).
These symptoms developed 6–8 min after the injection of LPS
(i.e., the peak platelet accumulations in the liver and lung
preceded these signs of shock). The severity of the shock was
completely abrogated in mice given Clo-Lip (Table 2).
3.4. Recovery of the response to LPS in Clo-Lip-treated mice
Mice treated with Clo-Lip displayed a progressive recovery
in their number of F4/80-positive cells (Fig. 5). In the liver,
these cells showed a full restoration to their initial level at 20after an intravenous injection of saline or LPS (0.5 mg/kg). Livers and lungs were
wn at two different magnifications. The strength of Pm-1 staining (brown) was
soidal vessels. In the lung, it is localized to capillaries in both saline- and LPS-
ted mice, in line with the observation that the normal level of 5HT is much higher
Fig. 1). It was also notable that capillaries in the lung of LPS-treated mice were
Table 2
Effects of macrophage depletion by Clo-Lip on LPS-induced anaphylaxis-like
shock
Treatment Shock score
Saline→LPS 3, 3, 3, 4, 4
Clo-Lip→LPS 0, 0, 0, 0, 0
Two groups of mice (n=5 each) were intravenously injected with saline or Clo-
Lip (diluted 8-fold, 0.2 ml/mouse). Then, 2 days later, LPS was injected
intravenously (1 mg/kg). The shock score indicates the maximum points
allocated for the signs of shock observed within 30 min of the LPS injection.
Fig. 5. Recovery in F4/80-positive cells in the liver after Clo-Lip-treatment. Clo-
Lip (diluted 8-fold) (0.2 ml/mouse) was injected intravenously, and livers were
taken at the indicated times after the Clo-Lip treatment. The livers were
subjected to immunostaining with F4/80 antibody, and representative results are
shown. The livers had nearly recovered their initial level of F4/80-positive cells
(brown) at 20 days after the Clo-Lip injection.
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were observed at 20 days, but not at 12 days, after the Clo-Lip
treatment (Table 3). Moreover, the HPA response observed at 12
days was small, but that at 20 days was as strong as in non-Clo-
Lip-treated mice (Fig. 6).
4. Discussion
The findings in the present study may be summarized as
follows. (i) In mice whose platelet count had been reduced by
Pm-1, the LPS-induced rapid shock was prevented almost
entirely. (ii) The existence of LPS-induced HPA and PPA was
confirmed by immunostaining. (iii) In control mice, F4/80-
positive cells were abundant in the liver but hardly detectable in
the lung, and these hepatic F4/80-positive cells were largely lost
after injection of Clo-Lip. (iv) In mice treated with Clo-Lip,
both HPA (but not PPA) and the anaphylaxis-like rapid shock
induced by LPS were largely prevented. (v) The level of F4/80-
positive cells in the liver was restored at 20 days (but not at 12
days) after Clo-Lip treatment, and the initial magnitude of the
HPA response to LPS was also restored at 20 days (but not at 12
days). These results are discussed in the following paragraphs.
As described in Introduction, LPS induces a biphasic
accumulation of platelets in the liver (i.e., a rapid HPA followed
by a slow HPA) [7,9]. Previously, we demonstrated that F4/80-
positive cells in the liver (hepatic macrophages; i.e., Kupffer
cells) are required for the slow HPA [13]. In the present study,
F4/80-positive cells in the liver were shown to be involved in
the rapid HPA, too, indicating that Kupffer cells are a
prerequisite for both the rapid and the slow HPA. However,
the molecular mechanisms underlying these two HPA responses
to LPS may be different, even if Kupffer cells are important for
both responses.Table 3
Recovery of shock responses to LPS after treatment with Clo-Lip
Treatment Shock scores
Days after Clo-Lip treatment
12 days 20 days
Saline→LPS 3, 3, 4, 4, 4 3, 3, 4, 4, 5
Clo-Lip→LPS 0, 1, 1, 1, 2 3, 4, 4, 4, 4
Four groups of mice (n=5 each) were intravenously injected with saline or Clo-
Lip (diluted 8-fold, 0.2 ml/mouse). Then, 12 or 20 days later, LPS was injected
intravenously (1 mg/kg). The shock score indicates the maximum points
allocated for the signs of shock observed within 30 min of the LPS injection.In the present study, the involvement of platelets in the LPS-
induced anaphylaxis-like rapid shock was confirmed by a
platelet-depletion experiment. However, as described in Intro-
duction, we think that although the HPA and PPA themselves
are not the direct cause of the shock, the degradation of platelets
in the liver and/or lung is involved in the rapid shock. The
magnitude of the HPA is smaller than that of the PPA in terms of
nmol 5HT per g of tissue. However, as calculated in Results, the
total amount of 5HT (i.e., the total number of platelets)
accumulated is quite similar between liver and lung, or perhaps
slightly greater in liver than in lung. In addition, a low dose of
Klebsiella O3 LPS (20 μg/kg) induces a maximal accumulation
of 5HT in the liver without its accumulation in the lung [8]. At
larger doses of this LPS (more than 20 μg/kg), the 5HT
accumulation increases dose-dependently in the lung (up to 500
μg/kg), but decreases dose-dependently in the liver [8]. In the
present study, the prevention of HPA alone (by Kupffer cell
depletion) completely abolished the rapid shock. These results
indicate that both the accumulation of platelets and their ensuing
degradation are more sensitive to LPS in the liver than in the
lung, and that a prevention of HPA is sufficient to abolish the
LPS-induced rapid shock (at least at the dose of LPS used in theFig. 6. HPA and PPA responses to LPS at 12 and 20 days after Clo-Lip-
treatment. Mice were separated into 4 groups at day 0 (4 mice in each group).
Clo-Lip (8-fold-diluted) was given intravenously (0.2 ml/mouse) to two groups
(to one group at day 0 and to another group at day 8). At day 20, saline or LPS
(0.5 mg/kg) was injected intravenously, and mice were killed by decapitation at
5 min after the injection. Each value is the mean±S.D. for 4 mice. *Pb0.01 vs.
S, #Pb0.05 vs. LPS alone, $Pb0.05 vs. Clo-Lip (12 days)→LPS.
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would induce rapid shock by inducing platelet degradation in
the lung even when HPA is prevented by depletion of Kupffer
cells, although we have not done this experiment.
F4/80 and BM8 are markers for mature macrophages [23].
Yamamoto et al. [24] reported that in BALB/c mice (as used in
our study), BM8-positive cells returned to their normal level by
day 10–14 after Clo-Lip-treatment. A similar, but somewhat
later, recovery was noted in our study: a full recovery of F4/80-
positive cells was seen at 20 days (but not at 12 days) after Clo-
Lip injection. This might be due to the use of different markers:
in other words, the functional restoration of Kupffer cells may
take longer than that of the BM8 maker.
After LPS injection, 5HT accumulated in a much greater
amount in the lung than in the liver in terms of nmol/g (Fig. 3),
suggesting that platelets accumulate in much greater numbers in
the lung than in the liver in terms of g tissue weight. However,
the number of F4/80-positive macrophages was very small in
the lung, and there was no detectable effect of Clo-Lip on the
LPS-induced PPA, suggesting that macrophages are not
involved in the mechanism underlying PPA. At present, we
have little data to explain the mechanism underlying PPA.
However, it was notable that platelets were already present at a
significant level in the lung of unstimulated mice (compare the
5HT levels in the lung and liver at time 0 in Fig. 1 and note the
strength of Pm-1 immunostaining in the lung of saline-treated
mice in Fig. 4). Hence, we speculate that the platelets already
present in the lung may somehow be involved in the further
accumulation of platelets in this organ. Indeed, platelets
mutually stimulate each other to form an aggregation (i.e.,
pre-existing platelets in the lung and platelets in the blood may
mutually stimulate each other, resulting in their extensive
accumulation within the lung). Incidentally, pretreatment of
mice with a muramyldipeptide (MDP, the minimal structural
moiety of bacterial peptidoglycan for various immunological
activities) augments both the platelet response and the
anaphylaxis-like shock induced by LPS [9]. In addition, such
shock can be induced in C3H/HeJ mice possessing a mutation in
the Tlr4 gene [25,26], suggesting that the platelet response to
LPS is not mediated by Toll-like receptor 4, a representative
pathogen-recognition molecule [6].
Instead, we earlier proposed the hypothesis that the lectin
pathway that forms C3 convertase from C4 and C2 is involved
in the rapid HPA and PPA induced by LPS, and that C5 may be
involved in the degradation or destruction of platelets [8].
However, we have no data to suggest how C3 convertase might
induce HPA and PPA. Recently, Hoffmeister et al. [27] reported
that the interaction between CR3 (complement iC3b receptors)
on Kupffer cells and clustered GPIb on chilling-activated
platelets results in the hepatic clearance of platelets when chilled
platelets are intravenously injected into mice. It would be of
interest to examine whether such a mechanism is involved in the
“rapid HPA”. However, at present, we have insufficient
information to guide us towards the molecular mechanism
underlying the HPA, or the PPA, induced by LPS.
Finally, approximately 200,000 patients develop gram-
negative sepsis each year in the USA [28]. These patientsmay develop acute respiratory distress syndrome (ARDS, about
one-quarter of the patients) or multiple organ failure (MOF)
including hepatitis. It has been suggested that in addition to
neutrophils and macrophages, platelets may be involved in the
pathology of ARDS [29] and MOF [30]. The present findings
on HPA and PPA may provide information concerning the
possible roles played by platelets in these diseases.
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